The Iran Pharmaceuticals and Healthcare Report

    • Independent 5-year pharmaceutical and healthcare industry forecasts for Iran.
    • Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Iranian pharmaceutical and healthcare industry.
    • Competitive intelligence, Iranian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Iranian market.

The Iran Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2012 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Iran Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Iranian pharmaceutical and healthcare industry.

" "We find the Pharmaceuticals & Healthcare Report very useful in benchmarking our company against competitors. It also provides us with a lead to future business opportunities." "
Hussain Malkawi, Sales & Marketing Manager HPD/ MN Gulf Region

Key Benefits of Report

    • Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Iran to test other views – a key input for successful budgeting and strategic business planning in the Iranian pharmaceutical and healthcare market.
    • Target Business Opportunities & Risks in the Iranian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Iran.
    • Exploit The Latest Competitive Iranian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Iran.

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

  • Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
  • Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
  • OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
  • Generics market (US$bn)/ as % of total market
  • Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

BMI's Executive Summary

[TOP]

The Iranian pharmaceutical market is characterised by its relatively strong domestic industry, which meets the bulk of local demand in volume terms. Multinationals are present through imports, although improved intellectual property and regulatory conditions may attract some investment in local facilities. However, although basic care is widely accessible, the patchy quality of primary care coverage continues to reduce patients' access to drugs and thus negatively affects the overall drug market's value and volume. In the meantime, patented and prescription drugs will continue to dominate the marketplace for as long as hospitals remain the primary access points to healthcare.

By 2012, the overall drug market is expected to be valued at US$2.62bn, up from an estimated US$1.79bn in 2007. Generics will gain a couple of percentage points in terms of market share, with new patented drugs continuing to be sidelined by restrictive reimbursement policies. Nevertheless, Iran's large and rapidly growing population will be instrumental in driving the expansion of the pharmaceutical market as a whole, as will be the likely increase in drug prices, which are presently among the lowest in the region. Additionally, if the government cuts fuel subsidies, domestic producers may face higher operating costs, which could stimulate a round of price increases.

Iran occupies tenth position in BMI's Business Environment Rankings for the Middle East and Africa (MEA) region, which has been substantially redesigned. Despite low per capita consumption of medicines and the large rural population, the sheer number of Iran's inhabitants represent a substantial commercial opportunities for companies willing to risk exposure to biased regulatory policies and inappropriate intellectual property (IP) environment. The dominance of the local industry in meeting the domestic demand will represent another drawback to foreign investment and involvement in the country.

In the meantime, the strong position of domestic firms will continue to stimulate the country's pharmaceutical exports, especially in the area of herbal medicines, which are making a mark on the international scene. Exports will receive government encouragement and investment in production facilities, with former Soviet Union and North African states being the prime export destinations. On the other hand, although some multinationals are planning on setting up local manufacturing plants, Iran's unsettled political climate will remain a major deterrent to such ventures.

Contents

[TOP]

Chapter 1 - Executive Summary

Iran Pharmaceuticals & Healthcare Industry SWOT

Iran Economic Industry SWOT

Iran Business Environment SWOT

Chapter 2 - Iran: Business Environment Ranking

Table: Business Environment Ranking: Middle East And Africa

Business Environment Ranking

Chapter 3 - Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property

Pricing And Reimbursement

Chapter 5 - Industry Developments

Healthcare Sector

Epidemiological Trends

Pharmaceutical Industry

International Co-operation

Company Activity

Drug Development

Chapter 6 - Industry Forecast Scenario

Key Growth Factors - Pharmaceutical Sector

Overall Market Forecast

Table: Iran Drug Expenditure Forecasts

Table: Economic Activity

Prescription And OTC Market Forecast

Table: OTC Market Forecasts

Table: Prescription Market Forecasts

Generics Market Forecast

Table: Generics Market Forecasts

Import/Export Market Forecast

Other Healthcare Data Forecasts

Table: Iran Healthcare Forecasts

Chapter 7 - Country Snapshot: Iran Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Table: Healthcare: Vital Statistics

Table: Healthcare: Expenditure

Section 3: Labour Market And Spending Power

Table: Employment Indicators

Table: Consumption And Stratification

Table: Wages Per Year

Chapter 8 - Competitive Landscape

Chapter 9 - Company Profiles

Darou Pakhsh

Iran Pharmaceutical Development & Investment Company (IPDIC)

Pars Darou

Pharmieco

Chapter 10 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Pharmaceutical Industry

Sources

Chapter 11 - Appendix: Regional Demographic Data

Table: The Long View: Data Over The Economic Cycle (2000-2007)

Table: Population

Table: Household Spending Per Capita, US$

Table: Private Consumption Per Capita, US$ PPP

Table: Market Size, GDP, US$bn

Competitive Landscape for Middle East & Africa Pharmaceuticals and Healthcare: Sample of Companies Ranked

[TOP]

Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.

Network of Middle Eastern and African Pharmaceutical & Healthcare Sources

[TOP]

BMI's Middle Eastern & African Pharmaceutical & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include:

 

Read about our other Pharmaceuticals & Healthcare Reports

Asia Europe Middle East & Africa The Americas
UK
UAE
USA
[top]

 

Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 24 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.